We are live on ! Find out more
KYMR icon

Kymera Therapeutics
KYMR

121 hedge funds and large institutions have $1.39B invested in Kymera Therapeutics in 2022 Q4 according to their latest regulatory filings, with 16 funds opening new positions, 48 increasing their positions, 38 reducing their positions, and 21 closing their positions.

New
Increased
Maintained
Reduced
Closed

219% more call options, than puts

Call options by funds: $30.2M | Put options by funds: $9.44M

33% more funds holding in top 10

Funds holding in top 10: 3 → 4 (+1)

26% more repeat investments, than reductions

Existing positions increased: 48 | Existing positions reduced: 38

21% more capital invested

Capital invested by funds: $1.15B → $1.39B (+$243M)

5.75% more ownership

Funds ownership: 96.56% → 102.31% (+5.7%)

5% less funds holding

Funds holding: 127 → 121 (-6)

24% less first-time investments, than exits

New positions opened: 16 | Existing positions closed: 21

Holders
121
Holders Change
-6
Holders Change %
-4.72%
% of All Funds
1.95%
Holding in Top 10
4
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+33.33%
% of All Funds
0.06%
New
16
Increased
48
Reduced
38
Closed
21
Calls
$30.2M
Puts
$9.44M
Net Calls
+$20.7M
Net Calls Change
+$20M

Top Buyers

Rank Fund Capital Flow
1
ACA
Avoro Capital Advisors
New York
+$44.8M
2
Wellington Management Group
Wellington Management Group
Massachusetts
+$31.5M
3
Vanguard Group
Vanguard Group
Pennsylvania
+$21.3M
4
Fidelity Investments
Fidelity Investments
Massachusetts
+$13.9M
5
AG
Artal Group
Luxembourg
+$13.3M

Top Sellers

Rank Fund Capital Flow
1
AVLSA
Atlas Venture Life Science Advisors
Massachusetts
-$23.8M
2
PAMS
Pictet Asset Management (Switzerland)
Switzerland
-$10.5M
3
WA
Wasatch Advisors
Utah
-$6.09M
4
RG
Redmile Group
California
-$5.41M
5
American Century Companies
American Century Companies
Missouri
-$3.13M
Name Holding Trade Value Shares
Change 		Change in
Stake
Charles Schwab
26
Charles Schwab
California
$7.44M +$516K +19,348 +7%
Morgan Stanley
27
Morgan Stanley
New York
$5.94M +$1.73M +65,052 +38%
Norges Bank
28
Norges Bank
Norway
$5.54M – – –
Rafferty Asset Management
29
Rafferty Asset Management
New York
$5.38M +$958K +35,933 +20%
Bank of America
30
Bank of America
North Carolina
$5.16M +$2.17M +81,307 +65%
UBS Group
31
UBS Group
Switzerland
$5.06M +$4.08M +153,076 +308%
Two Sigma Advisers
32
Two Sigma Advisers
New York
$4.58M +$141K +5,300 +3%
UBS AM
33
UBS AM
Illinois
$4.48M +$321K +12,022 +7%
Voloridge Investment Management
34
Voloridge Investment Management
Florida
$3.49M -$1.17M -43,831 -24%
Citigroup
35
Citigroup
New York
$3.3M -$1.84M -68,956 -34%
N
36
Nuveen
North Carolina
$3.09M -$423K -15,850 -11%
Two Sigma Investments
37
Two Sigma Investments
New York
$2.97M -$275K -10,324 -8%
American Century Companies
38
American Century Companies
Missouri
$2.76M -$3.13M -117,496 -51%
WP
39
Woodline Partners
California
$2.5M – – –
IHAM
40
Integral Health Asset Management
New York
$2.5M +$2.67M +100,000 New
CSS
41
Cubist Systematic Strategies
Connecticut
$2.49M +$2.23M +83,494 +513%
GGHC
42
Gilder Gagnon Howe & Co
New York
$2.25M +$240K +8,992 +11%
Swiss National Bank
43
Swiss National Bank
Switzerland
$2.03M +$45.3K +1,700 +2%
TD Asset Management
44
TD Asset Management
Ontario, Canada
$1.98M +$24K +900 +1%
VOYA Investment Management
45
VOYA Investment Management
Georgia
$1.8M +$545K +20,435 +39%
Jane Street
46
Jane Street
New York
$1.75M +$247K +9,273 +15%
Manulife (Manufacturers Life Insurance)
47
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$1.66M -$3.28K -123 -0.2%
RhumbLine Advisers
48
RhumbLine Advisers
Massachusetts
$1.53M +$26.5K +993 +2%
Walleye Capital
49
Walleye Capital
New York
$1.31M +$1.4M +52,328 New
California State Teachers Retirement System (CalSTRS)
50
California State Teachers Retirement System (CalSTRS)
California
$1.11M +$13.8K +519 +1%
1
2
3 4 5

KYMR Hedge Fund Activity: Q4 2022 in Review

121 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Kymera Therapeutics (KYMR) for Q4 2022, worth a combined $1.39B — up 21% from $1.15B a quarter earlier.

Sellers outnumbered buyers: 21 funds closed out of KYMR and 16 opened new positions — a net loss of 5 holders — while 38 trimmed existing stakes and 48 added.

The largest buyer was Avoro Capital Advisors, adding an estimated $44.8M. The largest seller was Atlas Venture Life Science Advisors, cutting an estimated $23.8M.

  • 121 institutional investors held Kymera Therapeutics (KYMR) as of Q4 2022, down from 127 in Q3 2022.
  • Funds reported $1.39B of Kymera Therapeutics stock for Q4 2022, up 21% quarter-over-quarter.
  • 16 funds opened new Kymera Therapeutics positions in Q4 2022 and 21 closed out, a net change of -5 holders.
  • The largest Kymera Therapeutics buyer in Q4 2022 was Avoro Capital Advisors, an estimated $44.8M added.
  • The largest Kymera Therapeutics seller in Q4 2022 was Atlas Venture Life Science Advisors, an estimated $23.8M sold.

Based on aggregated 13F filings for Q4 2022.